Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a review.

3 , 5 Despite the crossover in the intent-to-treat (ITT) population, long-term follow-up (median, 76 months) of the monotherapy population (N = 4,922) showed a 12% improvement in DFS, a 15% improvement in TTDR, and a 13% improvement in OS that is approaching significance with letrozole relative to placebo in the ITT population ( Table 1 ). 5 Because of the crossover, the true benefit of letrozole therapy is likely not reflected in the ITT analysis.

also in 2,640 other papers